Novo Nordisk Inks A Major Obesity Deal
Digest more
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 medication injected daily instead of weekly.
Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing alcohol use, though high costs may limit broad access.
Alternative compounded versions of Novo Nordisk’s blockbuster weight-loss and diabetes drugs have hurt its sales, particularly in the U.S.
18hon MSN
California is not required by federal law to cover the cost of the weight loss drugs in its Medi-Cal program. Instead, the state opted to include them. Under Newsom’s proposed cuts, when Ozempic is prescribed to treat diabetes, it would still be covered by Medi-Cal.
7don MSN
The company’s blockbuster drugs helped it beat Wall Street’s expectations—while WeightWatchers declares bankruptcy. One day after WeightWatchers said that it would file for bankruptcy, weight-loss drug giant Novo Nordisk’s outlook is brightening.
8don MSN
Novo Nordisk on Wednesday managed the unusual feat of seeing its stock price rise after reducing its earnings outlook. But that’s reflective of the tough times the Danish maker of Ozempic and other weight-loss drugs has had.
Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases. See why NVO stock is a Buy.
A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and scarring in people with MASH, a serious liver disease.